Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (171)	5/22/2001 2:40:56 PM
From: Marty	Read Replies (1) \| Respond to of 204

From Raging Bull: After the death spiral financings and the handling of the warrants, the thing that worried me the most about NEOT was the complete absence of any recognition of them in the Alzheimer's scientific research community. You can point to this conference and that presentation but in the overwhelming number of other instances of independent articles or reviews of the research on Alzheimer's ... NEOT is not even mentioned. Here is a case in point: This is a link to a new very comprehensive report, "2000, Progress Report on Alzheimer's Disease, Taking the Next Step" put out by National Institute on Aging, National Institutes of Health U.S. Department of Health and Human Services Public Health Service National Institutes of Health National Institute on Aging alzheimers.org They mention a great number of other approaches, organizations, and researchers but there is not a word about Neotrofin, or Neotherapeutics that I could find. They even describe other trials they have done at UCI and not the SCAN trials for NEOT. Maybe someone else can find something in there and point it out if I missed it. Maybe someone can reconcile how it is that nobody else in the field seems to have any interest in what Neotherapeutics considers a breakthrough drug.